Sant'Ana Phelipe Gabriel Dos Santos, Araujo Ariane Moreira, Pimenta Cynthia Teixeira, Bezerra Mário Lúcio Pacheco Ker, Junior Sílvio Pereira Borges, Neto Viviana Martins, Dias Janaina Sousa, Lopes Aline de Freitas, Rios Danyelle Romana Alves, Pinheiro Melina de Barros
Universidade Federal de São João Del Rei (UFSJ), Divinópolis, MG, Brazil.
Fundação Centro de Hematologia e Hemoterapia do Estado de Minas Gerais (HEMOMINAS), Divinópolis, MG, Brazil.
Rev Bras Hematol Hemoter. 2017 Jan-Mar;39(1):40-45. doi: 10.1016/j.bjhh.2016.09.007. Epub 2016 Oct 19.
This study aimed to describe and analyze clinical and laboratory characteristics of patients with sickle cell anemia treated at the Hemominas Foundation, in Divinópolis, Brazil. Furthermore, this study aimed to compare the clinical and laboratory outcomes of the group of patients treated with hydroxyurea with those patients that were not treated with hydroxyurea.
Clinical and laboratorial data were obtained by analyzing medical records of patients with sickle cell anemia.
Data from the medical records of 50 patients were analyzed. Most of the patients were female (56%), aged between 20 and 29 years old. Infections, transfusions, cholecystectomy, splenectomy and systemic arterial hypertension were the most common clinical adverse events of the patients. The most frequent cause of hospitalization was painful crisis. The majority of patients had reduced values of hemoglobin and hematocrit (8.55±1.33g/dL and 25.7±4.4%, respectively) and increased fetal hemoglobin levels (12±7%). None of the clinical variables was statistically significant on comparing the two groups of patients. Among hematological variables only hemoglobin and hematocrit levels were statistically different between patients treated with hydroxyurea and untreated patients (p-value=0.005 and p-value=0.001, respectively).
Sickle cell anemia requires treatment and follow-up by a multiprofessional team. A current therapeutic option is hydroxyurea. This drug reduces complications and improves laboratorial parameters of patients. In this study, the use of the drug increased the hemoglobin and hematocrit levels of patients.
本研究旨在描述和分析在巴西迪维诺波利斯的Hemominas基金会接受治疗的镰状细胞贫血患者的临床和实验室特征。此外，本研究旨在比较接受羟基脲治疗的患者组与未接受羟基脲治疗的患者的临床和实验室结果。
通过分析镰状细胞贫血患者的病历获得临床和实验室数据。
分析了50例患者的病历数据。大多数患者为女性（56%），年龄在20至29岁之间。感染、输血、胆囊切除术、脾切除术和系统性动脉高血压是患者最常见的临床不良事件。住院最常见的原因是疼痛性危机。大多数患者的血红蛋白和血细胞比容值降低（分别为8.55±1.33g/dL和25.7±4.4%），胎儿血红蛋白水平升高（12±7%）。在比较两组患者时，没有临床变量具有统计学意义。在血液学变量中，只有接受羟基脲治疗的患者和未接受治疗的患者之间的血红蛋白和血细胞比容水平存在统计学差异（p值分别为0.005和0.001）。
镰状细胞贫血需要多专业团队进行治疗和随访。目前的一种治疗选择是羟基脲。这种药物可减少并发症并改善患者的实验室指标。在本研究中，使用该药物提高了患者的血红蛋白和血细胞比容水平。
